Source: BioSpace

Aculys: NEURELIS SIGNS EXCLUSIVE LICENSING AGREEMENT WITH ACULYS PHARMA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF VALTOCO (DIAZEPAM NASAL SPRAY) IN JAPAN AND THE ASIA-PACIFIC REGION

Neurelis, Inc. announced that it has signed an exclusive licensing agreement with Aculys Pharma, Inc. for the development and commercialization of VALTOCO® (diazepam nasal spray) in Japan and the Asia-Pacific region which includes Australia, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, New Zealand, Philippines, South Korea, Thailand and Vietnam.

Read full article »
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Hidemasa Tanigaki's photo - CEO of Aculys

CEO

Hidemasa Tanigaki

CEO Approval Rating

90/100

Read more